Previous 10 | Next 10 |
CUPERTINO, Calif. , July 17, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged that the submission of DURECT's full response to the Complete Response Letter (CRL) it previously received from FDA re...
Unlike many prior proposals that would have minimal impact in controlling the cost of pharmaceuticals, two recently proposed legislative actions could meaningfully reduce Medicare drug spending. One is aimed at Medicare Part D , which represented $100 billion of the $130 billion spent by ...
CUPERTINO, Calif. , June 27, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has submitted a full response to the Complete Response Letter (CRL) it previously received from U.S. Food and Drug Administration (FDA) related to POSIMIR ® (bupivacaine extended-r...
CUPERTINO, Calif. , June 25, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it received approval from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") to transfer the listing of the Company's common stock from the Nasdaq Global Marke...
CUPERTINO, Calif. , June 20, 2019 /PRNewswire/ -- DURECT Corporation ("DURECT" or the "Company") (Nasdaq: DRRX) today announced that it has entered into a securities purchase agreement with certain investors pursuant to which, subject to the terms and conditions expressed therein, th...
CUPERTINO, Calif. , June 18, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has completed dosing the 90 mg cohort of severe AH patients in its ongoing DUR-928 Phase 2a clinical trial, and that after reviewing safety and pharmacokinetic (PK) data from the co...
CUPERTINO, Calif. , May 16, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , Chief Executive Officer, and Michael H. Arenberg , Chief Financial Officer, will be participating in the 20 th Annual B. Riley FBR Institutional Investor Confer...
DURECT Corp, Inc. (DRRX) Q1 2019 Earnings Conference Call May 08, 2019, 08:30 ET Company Participants Michael Arenberg - CFO James Brown - Co-Founder, CEO, President & Director Paul Kwo - Professor, Medicine & Director, Hepatology, Stanford University Steven Flamm - Nor...
CUPERTINO, Calif. , May 7, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced preliminary data from the ongoing DUR-928 alcoholic hepatitis (AH) Phase 2a clinical trial. On Wednesday, May 8 th at 8:30 a.m. Eastern Time , DURECT will host a Key Opinion Le...
Durect (NASDAQ: DRRX ): Q1 GAAP EPS of -$0.04 beats by $0.01 . More news on: DURECT Corporation, Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis PR Newswire DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial CUPERTINO, Calif. , May ...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 171.6% to $0.1657 on volume of 180,907,472 shares AMC Entertainment Holdings Inc. Class A (AMC) rose 84.4% to $9.57 on volume of 174,658,682 shares Plug Power Inc. (PLUG) rose 45.9%...
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update PR Newswire - FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Ea...